Denali’s DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
Latest Ratings for DNLI
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Morgan Stanley | Maintains | Overweight | |
| Sep 2021 | Oppenheimer | Initiates Coverage On | Outperform | |
| Aug 2021 | Morgan Stanley | Maintains | Overweight |
